
FDA approves Cosentyx as first anti-IL-17 biologic for polymyalgia rheumatica
Key Takeaways
- Regulatory clearance positions secukinumab as the first IL-17 biologic for PMR, addressing relapse-prone, steroid-dependent disease and the morbidity associated with prolonged glucocorticoid exposure.
- REPLENISH showed sustained remission at week 52 in 40.5% with secukinumab 150 mg versus 20.5% with placebo after a 24-week taper, alongside steroid-sparing outcomes.
The FDA approved Cosentyx for polymyalgia rheumatica after 40.5% of trial patients reached sustained remission at week 52 vs. 20.5% on placebo.
Adults with polymyalgia rheumatica (PMR) who have not responded adequately to corticosteroids or who cannot tolerate a steroid taper have a new treatment option after the FDA approved Cosentyx (secukinumab) 150 mg for the condition, Novartis announced today in a news release. Cosentyx is the first and only anti-IL-17 biologic approved for the disease.
PMR is an inflammatory disease that primarily affects adults over 50 and is characterized by acute pain and stiffness in the shoulders, neck and hips. Approximately
What the REPLENISH trial found for Cosentyx in PMR
The approval is based on REPLENISH, a placebo-controlled Phase III study across 27 countries that tested Cosentyx 300 mg and 150 mg, each with a 24-week steroid taper. The data were published in the New England Journal of Medicine and presented at the European Alliance of Associations for Rheumatology Congress earlier this year.
The trial met its primary end point. At week 52, after completing the steroid taper, 40.5% of patients on Cosentyx 150 mg had achieved sustained remission, compared with 20.5% of those on placebo. Key secondary end points included complete sustained remission, the adjusted annual cumulative steroid dose and time to first escape or rescue treatment. Novartis said Cosentyx demonstrated steroid-sparing effects vs. placebo.
“Patients with PMR are at increased risk of poor outcomes related to steroids, and the prospect of months or years of additional steroids is disheartening,” said John Stone, M.D., M.P.H., professor of medicine at Harvard Medical School and Massachusetts General Hospital and global principal investigator for the REPLENISH trial. “For too long, treatment options beyond glucocorticoids have been limited.”
Novartis said safety in the trial was consistent with the drug’s established profile. Serious side effects occurred in 15.9% of patients in the Cosentyx 150-mg group and 14.2% of those in the placebo group. Patients on Cosentyx 150 mg had higher rates of hypersensitivity reactions, including eczema, dermatitis, rash and urticaria (14% vs. 9%), and urinary tract infections (13% vs. 7%) than those on placebo. One patient in the 150-mg group had a serious urinary tract infection, and a fatal case of cryptococcal meningitis occurred in a patient treated with Cosentyx.
Where Cosentyx fits in the PMR treatment landscape
Cosentyx is not the first PMR biologic. In 2023, the FDA
Cosentyx is also approved for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis and hidradenitis suppurativa. The PMR indication is already approved in the European Union, and reviews are ongoing in Japan and other countries.
What the Cosentyx PMR approval means for payers
The approval comes as Medicare prepares to set a negotiated price for Cosentyx. The Centers for Medicare and Medicaid Services
“PMR can make remarkably ordinary things hard: getting out of bed, getting dressed, lifting your arms, getting through the day. For years, patients have had too few treatment options,” said Seth Ginsberg, co-founder and president of the Global Healthy Living Foundation and CreakyJoints. “The approval of secukinumab offers patients and their clinicians a new therapeutic option and the opportunity for more individualized care.”
Related to this article







